This review summarises and discusses recent findings concerning the pathophysiology, clinical presentation, diagnosis, treatment, and outcome of SARS-CoV-2-associated Guillain-Barre syndrome (SC2-GBS). By the end of December 2020, at least 220 patients with SC2-GBS have been published in 95 papers. SC2-GBS is most likely secondary due to an immune reaction against SARS-CoV-2 since the virus has not been found in the CSF of any SC2-GBS patient so far reported. SC2-GBS occurs in each age group and does not differ from non-SC2-GBS regarding clinical presentation and treatment, but the outcome of SC2-GBS is worse compared to non-CS2-GBS patients, and the prevalence/incidence of GBS most likely increased since the outbreak of the pandemic. Early diagnosis of SC2-GBS is warranted to apply appropriate treatment in due time and to improve the overall outcome from the infection.
【저자키워드】 COVID-19, SARS-CoV-2, immunoglobulins, Nerve conduction, Guillain-barrè syndrome, 【초록키워드】 Treatment, pandemic, Infection, Diagnosis, outcome, virus, pathophysiology, outbreak, Patient, age, patients, CSF, immune reaction, IMPROVE, not differ, reported, occur, concerning, recent finding, 【제목키워드】 patients with COVID-19,